Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib combined with radiotherapy for EGFR-mutant stage III lung adenocarcinoma
ChiCTR-PPC-15006771Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of icotinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started Jul 2015; status: recruiting.
02
Drugs
icotinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR-PPC-15006771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PPC-15006771.